NeoCart Phase 2 Clinical Trial
Launched by HISTOGENICS CORPORATION · Oct 19, 2007
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients presenting with symptomatic knee pain indicative of an articular cartilage injury and able and willing to give informed consent.
- Exclusion Criteria:
- • Patients with any previous surgical treatment other than debridement or microfracture of the study cartilage defect.
About Histogenics Corporation
Histogenics Corporation is a pioneering biotechnology company focused on developing innovative regenerative medicine solutions to enhance healing and recovery in orthopedic and musculoskeletal conditions. With a commitment to advancing cell-based therapies, Histogenics utilizes its proprietary technologies to create products that aim to restore damaged tissue and improve patient outcomes. The company is dedicated to conducting rigorous clinical trials to validate the safety and efficacy of its therapies, positioning itself as a leader in the field of regenerative medicine. Through strategic partnerships and a robust research pipeline, Histogenics strives to transform the treatment landscape for patients suffering from debilitating injuries and conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
San Francisco, California, United States
Portland, Oregon, United States
Bloomington, Minnesota, United States
West Point, New York, United States
Durham, North Carolina, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials